


PHARMACEUTICAL 2021

CytomX Therapeutics Inc. Rank 132 of 409







PHARMACEUTICAL 2021

CytomX Therapeutics Inc. Rank 132 of 409



The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 150% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -24%, being 331% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	324,013
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	100,924
Liabilities, Non-Current	207,936
Other Assets	26,751
Other Compr. Net Income	-104
Other Expenses	-13,911
Other Liabilities	0
Other Net Income	1,809
Property and Equipment	6,950
Research and Development	112,936
Revenues	100,362
Selling, General and Administrative Expense	36,031

Output Variable	Value in 1000 USD
Assets	358,663
Liabilities	308,860
Expenses	135,056
Stockholders Equity	49,803
Net Income	-32,885
Comprehensive Net Income	-32,937
Economic Capital Ratio	-24%